https://register-of-charities.chari...-charities/-/charity-details/1045921/trustees Just noting that the Cochrane Collaboration is a charity governed by the Charity Commission of England and Wales. Many of the Trustees appear to have changed in November 2024. Perhaps the new trustees are not aware in any detail of the September decision on the Larun et al review; perhaps to the contrary, they are supportive of it. Perhaps some of the trustees who stood down in 2024 were not supportive of the decision and may be concerned about the events of December. Person, role, date of appointment, other trusteeships Dr Susan Phillips, Chair, 15 July 2024, None on record Professor Vanessa Jordan-Cole, Trustee, 25 November 2024, None on record Dr Giordano Perez Gaxiola, Trustee, 25 November 2024, None on record Professor Joerg Meerpohl, Trustee, 25 November 2024, None on record Nigel Jones, Trustee, 12 August 2024, THE GRACE MEMORIAL TRUST, West Sussex Mind Professor Gillian Leng, Trustee, 01 October 2022, THE ROYAL SOCIETY OF MEDICINE Dr Wendy Sue Levinson, Trustee, 01 October 2022, None on record Emma Eleanor Beatrice Persad, Trustee, 29 November 2021, None on record Professor Tamara Kredo, Trustee, 24 August 2020, None on record Dr Juan Victor Ariel Franco, Trustee, 24 August 2020, None on record
https://register-of-charities.chari...s/-/charity-details/1045921/financial-history On the finances of the Cochrane Collaboration, it appears that they had no UK government contracts and received no UK government grants, at least up to the end of 2023. It did however receive 9 million pounds of income from 'charitable activities' in 2023. Excerpts from the 2023 Annual Report Cochrane's governing body is the Governing Board (the Board) and members of the Board are the Charity’s Trustees. The Board determines the overall strategic direction in line with the charitable objectives and governs the Charity on behalf of the organization’s members. The Board scrutinises the management functions that have been delegated to the Executive Leadership Team. A framework sets out the authority delegated to the Chief Executive Officer (CEO) and the Editor in Chief (EIC) by the Board. All Trustees adhere to a Governing Board Charter and Code of Conduct for Trustees and take part in regular training and development. In September 2023, the Governing Board agreed that the Cochrane Council would not continue to operate after the end of 2023. A working group made up of members of the Council and the Governing Board agreed to work together during the first half of 2024 to develop new and improved ways of engaging with the Cochrane community. The Future Engagement Mechanisms Working Group met on 12 December 2023 and again on 21 February 2024, it will develop a proposal to present to the Board during the first half of 2024. Following our response to the World Health Organization (WHO) consultation on global clinical trials policy and our ongoing advocacy and partnership work with WHO, Cochrane’s Editor in Chief was appointed to a new WHO Technical Advisory Group on Development of Guidance on Best Practices for Clinical Trials (in a personal capacity). This will be a key opportunity to input into this policy priority, which was initiated and supported by several governments at the World Health Assembly in May 2022. We are in the process of formalising a partnership with the Pan American Health Organization (PAHO), which is expected to be agreed and signed in 2024. Cochrane sent a delegation, comprising Cochrane leadership and representatives of Cochrane Rehabilitation and Cochrane Switzerland, to the 76th World Health Assembly (WHA76) in May 2023. This gave us the opportunity to meet with key partners and build our network. WHA76 also marked the historic passing of the first ever resolution on strengthening rehabilitation in health systems. To commemorate the occasion, Cochrane supported a side event organised with NGOs and professional associations working in the field of rehabilitation and sponsored by five member states. Prof Stefano Negrini, Director of Cochrane Rehabilitation, represented Cochrane and spoke on the importance of using the best possible evidence for rehabilitation. In November 2023, we hosted a workshop on initiating the Cochrane Scientific Strategy at WHO headquarters in Geneva. The workshop was attended by 18 WHO officials including the Director of Special Programmes on Primary Healthcare, the Director of the Health and Migration team, the Director of the Department for Social Determinants of Health and the Director of Quality Assurance of Norms and Standards. Through this, we were able to build new relationships and strengthen existing relationships throughout WHO. We continue to have follow-up meetings on the ongoing development of the Scientific Strategy.
More excerpts from the 2023 Annual Report: How to spin a debacle as a positive! - that's the masks review with its Altmetric score of 26,000. Number 2 on the list had an Altmetric score of just 3,000. Moving to Open Access will presumably require a different funding model. This seems to be 'fundraising' - which makes sense, as 11 million pounds is relatively small change for an organisation like Cochrane to raise.
What are the charitable activities? And is £9m in 2023 a significantly different amount to what they received by those in previous years?
